Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2023 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial | LANCET ONCOLOGY |